This post is from a suggested group
Addressing Mortality: The Role of Novel Drugs and Dialysis Centers in the UK Calciphylaxis Market
The UK Calciphylaxis Market is grappling with the challenge of managing a rare but highly fatal condition, predominantly among patients with End-Stage Kidney Disease (ESKD) on dialysis. The UK’s relatively centralized National Health Service (NHS) provides a unique framework for both challenges and opportunities in this market. The market size is directly correlated with the growing prevalence of chronic kidney disease and the aging population, which together increase the pool of at-risk patients. Dialysis centers are at the frontline of diagnosis and initial management, given the strong association with ESKD. These centers are crucial for the early detection of calciphylaxis lesions, which is critical for patient survival. Current management in the UK, similar to other developed nations, lacks a specific licensed drug, relying on a bundle of supportive care measures: intensive wound care, pain management,…